An observational study in Dialysis Access Malfunction and Arteriovenous Fistula, sponsored by Istanbul University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Istanbul University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Arteriovenous Fistula with a site in Turkey — 2 open to participants now, 2 under way, none of them phase 3. Arteriovenous Fistula · Turkey.
Among the 22 studies in Arteriovenous Fistula with a site in Turkey, this one is the only one that started in 2026, is one of 6 observational ones, and was the 22nd registered.
248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.
Browse Arteriovenous Fistula studies →2 of the 22 studies in Arteriovenous Fistula with a site in Turkey are open now. Recruiting first, the newest first:
Lifetech Scientific (Shenzhen) Co., Ltd. · Sites in Turkey, Germany, Italy
Ages 18–85
Karadeniz Technical University · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 504 is above the median of 100 across 71 observational studies indexed under Arteriovenous Fistula.
Median enrollment 60 across the 16 interventional studies, 148 across the 6 observational. Of the 19 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 22 have an industry lead sponsor. The 10 most frequent:
Istanbul University is the lead sponsor of 512 studies on the registry; 76 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Istanbul University has 1 study filed under Arteriovenous Fistula — fewer than ten, so there is no comparison to draw.
1 of the studies in Arteriovenous Fistula with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06099015Lifetech Scientific (Shenzhen) Co., Ltd.Cera™ Vascular Plug System Post-Market Clinical Follow-Up | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Arteriovenous Fistula with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Recommendations regarding tourniquet use in arteriovenous fistula (AVF) cannulation vary across guidelines. In general, the use of a tourniquet is recommended for all needle insertions into an AVF unless the fistula is aneurysmal. In contrast, tourniquets are not required for arteriovenous grafts. A tourniquet should be applied to assess vessel depth and direction in order to guide needle insertion. However, prolonged application must be avoided to prevent thrombosis due to impaired venous return and blood stasis. During difficult cannulations, the tourniquet may need to be released and reapplied to minimize distal ischemica
There is no consensus, therefore the recommendations in the guidelines are inconsistent on the use of a tourniquet during AVF cannulation. This suggests that tourniquet use during cannulation is largely guided by unit-specific written protocols and the clinical judgment of nurses. A recent systematic review emphasized the lack of standardized approaches and highlighted the importance of individualized, nurse-driven decision-making in vascular access management.
This study was conducted in a total of eight seven countries: Türkiye, Denmark, Peru, Netherlands, Portugal, Poland, and Greece.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Determine nurses' use of tourniquets during AVF cannulation and to identify the factors influencing their use.
Data were collected using a questionnaire developed by the researchers based on the literature
Time frame: Baseline
Confidence during AVF cannulation
The Visual Analogue Scale was used to assess nurses' confidence levels before cannulation, ranging from 0 (no confidence) to 10 (the highest confidence)
Time frame: Baseline
Plan to share: Undecided
Ran from Jun 2026 to primary completion in Nov 2026, 4 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.